A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A 6-week in-patient and out-patient study to test the effectiveness and safety of a new medication in the treatment of schizophrenia

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sunovion
• Treatments: Lurasidone Hydrochloride

Criteria

Inclusion Criteria:

• Satisfy DSM-IV criteria for schizophrenia as established by SCID-CV

• The patient must agree to a voluntary hospitalization duration of 31 days minimum at the start of the treatment

• If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception

Exclusion Criteria:

• The patient has used an investigational drug within the past 30 days

• The patient has participated in a previous study of this compound